Provectus Biopharmaceuticals (PVCT) News Today $0.07 +0.00 (+1.32%) As of 03:56 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock PVCT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - MorningstarJune 27, 2025 | morningstar.comMProvectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck CancerJune 26, 2025 | globenewswire.comProvectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of StockholdersJune 9, 2025 | globenewswire.comProvectus Biopharmaceuticals (OTCMKTS:PVCT) Stock Price Up 1% - Here's WhyJanuary 17, 2025 | marketbeat.comProvectus announces $3M seed financing round for VisiRoseJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | globenewswire.comProvectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest UpdateDecember 26, 2024 | marketbeat.comProvectus announces the launch of VisiRoseDecember 12, 2024 | markets.businessinsider.comProvectus Pharmaceuticals Aligns Leadership with Equity GrantsDecember 6, 2024 | markets.businessinsider.comProvectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 99.2% in NovemberNovember 28, 2024 | marketbeat.comProvectus Pharmaceuticals to Reveal Key 2024 UpdatesNovember 15, 2024 | markets.businessinsider.comProvectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProvectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallOctober 10, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual MeetingMay 21, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingMay 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 27, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and VaccinesMarch 12, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual MeetingMarch 7, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual MeetingFebruary 29, 2024 | globenewswire.comProvectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call TranscriptFebruary 23, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 15, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 15, 2024 | globenewswire.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesFebruary 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesFebruary 14, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine AdjuvantDecember 18, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Inc PVCTNovember 19, 2023 | morningstar.comMProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 15, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 15, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 13, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 13, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 6, 2023 | finance.yahoo.comProvectus Algae Enters Into Livestock Methane Reduction Space Commissioning First Demonstration Biomanufacturing PlantNovember 2, 2023 | benzinga.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingAugust 7, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 CongressAugust 1, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue SarcomasJune 28, 2023 | finance.yahoo.comPVCT - Provectus Biopharmaceuticals, Inc.June 3, 2023 | finance.yahoo.comProvectus: Q1 Earnings SnapshotMay 12, 2023 | chron.comProvectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative BacteriaApril 20, 2023 | finance.yahoo.comHucu.ai and Provectus expand their relationship into a multi-year partnershipApril 18, 2023 | technews.tmcnet.comLyophilization Services for Biopharmaceuticals Market Growing Demand and Trends 2023 to 2031March 29, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market Growth and Competitive Landscape 2023-2029March 27, 2023 | marketwatch.comFormer Estée Lauder Executive Joins Provectus Algae as Cosmetics Advisor Signalling Industry ExpansionMarch 21, 2023 | venturebeat.comVFive Areas Where AI Is Revolutionizing The Biopharmaceutical IndustryMarch 17, 2023 | forbes.comProvectus Algae Receives Strategic Investment from Biotech Leader CJ BioMarch 1, 2023 | venturebeat.comVRelative Strength Alert For Day One BiopharmaceuticalsFebruary 26, 2023 | nasdaq.comBiopharmaceutical Third Party Logistics (3PL) Market Size 2023 Will Touch A New Level In The Upcoming Year 2026February 19, 2023 | marketwatch.comShort Volatility Alert: Provectus BiopharmJanuary 24, 2023 | benzinga.com Get Provectus Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVCT Media Mentions By Week PVCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVCT News Sentiment▼-1.000.93▲Average Medical News Sentiment PVCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVCT Articles This Week▼10▲PVCT Articles Average Week Get the Latest News and Ratings for PVCT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BHST News GNLX News IVVD News TARA News ZNTL News MGNX News CRBP News SPRO News ONCY News IFRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PVCT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
